James Del Rosso, DO, and David G. Cotter, MD, PhD: Targeting the IL-31 Neuroimmune Pathway for Treating Prurigo Nodularis

November 13, 2025

Drs. Del Rosso and Cotter discuss how advances in the molecular understanding of Prurigo Nodularis have led to the development of targeted therapies that address the root causes of this chronic itch condition. Their presentation focuses on the role of the Interleukin-31 pathway, a key neuroimmune signaling pathway that drives itch and inflammation.

Topics Covered

The neuroimmune mechanisms underlying prurigo nodularis
The role of IL-31 in chronic itch and lesion formation
How targeted therapies interrupt itch signaling pathways
The shift toward disease-modifying treatments in prurigo nodularis

Explore Related Resources

Listen to the extended-cut podcast here

MORE EXPERT PERSPECTIVES IN PRURIGO NODULARIS:

Angela Lamb, MD: Breaking the Itch-Scratch Cycle in Prurigo Nodularis

Angela Lamb, MD, an associate professor of dermatology at the Icahn School of Medicine at Mount Sinai in New York, discusses recent advancements in understanding

David Cotter, MD, PhD: Patient Presentation and Clinical Trial Data for Prurigo Nodularis

Dr. Cotter, a board-certified dermatologist at Las Vegas Dermatology, presents a real-world case of Prurigo Nodularis, highlighting both the severity of disease presentation and the

Jenny Murase, MD: Assessing Symptoms and Presentation of Patients with Prurigo Nodularis

Dr. Murase reviews the clinical presentation of Prurigo Nodularis, a chronic inflammatory skin condition characterized by intensely pruritic nodules and significant disease burden. She outlines

Diego Ruiz Dasilva, MD, FAAD: Providing Treatment for Challenging Cases of Chronic Pruritus

Dr. Dasilva presents findings from a real-world case series evaluating treatment options for patients with treatment-resistant chronic pruritus, highlighting the marked efficacy of Nemolizumab. His

JCAD Archives